Azithromycin for eczema in children
Treatments studied
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This study tests whether the antibiotic azithromycin can help reduce eczema symptoms in children. It may be an option for children who have not responded to usual creams or ointments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child must be between 3 and 12 years old
- Diagnosed with mild to moderate atopic dermatitis (eczema)
- Not currently using whole-body treatments for eczema (like pills or injections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an oral medicine called roflumilast to see if it helps treat moderate to severe eczema in people aged 12 and up who haven't used other systemic treatments recently. It's a pilot study to check both safety and how well it works.
This study tests a new ointment containing probiotics (good bacteria) to see if it helps with eczema in children. It is a cream that is applied to the skin, and the goal is to see if it reduces the itching and redness.
This study tests a daily pill, abrocitinib, to see if it safely reduces severe eczema (atopic dermatitis) in children aged 2 to under 6 years. It may help when creams or other treatments haven't worked well enough.
This study tests an oral medication (EC-18) for moderate to severe atopic dermatitis (eczema) to see if it can improve symptoms like itching and skin rash. It may be an option for people whose eczema is not controlled by topical treatments.
This study compares two creams for treating mild to moderate eczema in children: crisaborole 2% and tacrolimus 0.1%. It aims to see which one is more effective and safe for your child.
This trial tests whether a cosmetic cream can reduce eczema flare-ups and is comfortable/safe to use on very dry, irritated, eczema-prone skin. It’s mainly for children who have had recent flare-ups and moderate eczema severity.
Hear when a new Atopic Dermatitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.